Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum9507710.26442/2075-1753_2018.9.39-46ArticlesСтатьиReview ArticlePractical use of non-steroid anti-inflammatory drugs in cephalgia treatment: clinical and scientific evidence reviewПрактическое применение нестероидных противовоспалительных препаратов при головных болях: обзор клинических и научных данныхSergeevA. VСергеевАлексей Владимирович

канд. мед. наук, ассистент каф. нервных болезней и нейрохирургии

sergeev.neuro@gmail.comI.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian FederationФГАОУ ВО «Первый МГМУ им. И.М.Сеченова»A.Ya.Kozhevnikov Clinic for Nervous Diseases15092018209VOL 20, NO9 (2018)ТОМ 20, №9 (2018)394628122021Copyright ©; 2018, Consilium MedicumCopyright ©; 2018, ООО "Консилиум Медикум"2018Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/95077

В неврологической практике нестероидные противовоспалительные препараты (НПВП) широко используются в терапии скелетно-мышечных вертеброгенных болевых синдромов. В то же время отмечаются сложности в определении необходимости и точек эффективного применения НПВП при разных формах головных болей, особенно при мигрени. Современные экспериментальные данные показывают, что обезболивающий эффект НПВП связан не только с периферической аналгезией, но и с действием на уровне заднего рога спинного мозга, нейронов ядра тройничного нерва. Эти механизмы могут объяснять эффективность НПВП при мигрени. В обзоре обсуждается место НПВП при различных головных болях, преимущества по профилю эффективность/безопасность быстродействующих форм НПВП, стратифицированный подход к обезболиванию.

cephalgianon-steroid anti-inflammatory drugsmigrainetension headachecervicogenic headachelornoxicamfast-acting non-steroid anti-inflammatory drugsголовная больнестероидные противовоспалительные препаратымигреньголовная боль напряженияцервикогенная головная больлорноксикамбыстродействующие формы нестероидных противовоспалительных препаратовAtchison J.W, Herndon C.M, Rusie E. NSAIDs for musculoskeletal pain management: current perspectives and novel strategies to improve safety. J Manag Care Spec Pharm 2013; 19 (9 Suppl. A): 1-19.WHO Normative Guidelines on Pain Management. 2007. http: //www.who.int/medicines/areas/quality_safety/delphi_study_pain_guidelinesLipton R.B, Stewart W.F, Stone A.M et al. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: A randomized trial. JAMA 2000; 284: 2599.The 3rd edition of the International Classification of Headache Disorders (ICHD-3). Cephalalgia 2018; 38 (1) 1-211.Tepper S.J., Dahlöf C.G, Dowson A et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004; 44 (9): 856-64.Acute migraine treatment in emergency settings. Comparative Effectiveness Review Summary Guides for Clinicians. Agency for Healthcare Research and Quality. www.ncbi.nlm.nih.gov/books/NBK164542/ (Accessed on November 25, 2013)/Evers S, Afra J, Frese A et al. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009; 16 (9): 968-81.Осипова В.В., Филатова Е.Г., Артеменко А.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журн. неврологии и психиатрии им. С.С.Корсакова. Спецвыпуски. 2017; 117 (1): 28-42]Сергеев А.В. Доказательная терапия приступа мигрени. Consilium Medicum. Неврология и Ревматология (Прил.). 2015; 1: 34-7.Colman I, Friedman B.W, Brown M.D et al. Parenteral dexamethasone for acute severe migraine headache: meta-analysis of randomised controlled trials for preventing recurrence. BMJ 2008; 336: 359.Lim S.S, Vos T, Flaxman A.D et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-96.Jensen R, Stovner L.J. Epidemiology and comorbidity of headache. Lancet Neurol 2008; 7: 354.Осипова В.В. Головная боль напряжения. Практическое руководство. М., 2009.Сергеев А.В. Лечение головной боли напряжения: от старых мифов к современной концепции. РМЖ. 2015; 12: 668-74.Bendtsen L, Evers S, Linde M et al. EFNS guideline on the treatment of tension-type headache - report of an EFNS task force. Eur J Neurol 2010; 17: 1318.Lampl C, Rudolph M, Deligianni C.I, Mitsikostas D.D. Neck pain in episodic migraine: premonitory symptom or part of the attack? J Headache Pain 2015; 16: 80.Bogduk N, Govind J. Cervicogenic headache: an assessment of the evidence on clinical diagnosis, invasive tests, and treatment. Lancet Neurol 2009; 8: 959.Табеева Т.Г. Сергеев А.В. Цервикогенная головная боль: патофизиология, клиника, подходы к терапии. Неврология, нейропсихиатрия, психосоматика. 2010; 2 (2): 19-26.Lord S.M, Barnsley L, Wallis B.J, Bogduk N. Third occipital nerve headache: a prevalence study. J Neurol Neurosurg Psychiatry 1994; 57: 1187.Aprill C, Axinn M.J, Bogduk N. Occipital headaches stemming from the lateral atlanto-axial (C1-2) joint. Cephalalgia 2002; 22: 15.Barnsley L, Lord S, Bogduk N. Comparative local anaesthetic blocks in the diagnosis of cervical zygapophysial joint pain. Pain 1993; 55: 99.Lipton R.B, Scher A.I, Steiner T.J et al. Patterns of health care utilization for migraine in England and in the United States. Neurology 2003; 60: 441-8.Baraldi C, Pellesi L, Guerzoni S et al. Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal. J Headache Pain 2017; 18 (1): 71.Pardutz A, Schoenen J. NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental Data. Pharmaceuticals (Basel) 2010; 3 (6): 1966-87.Brooks P.M, Day R.O. Nonsteroidal anti-inflammatory drugs differences and similarities. N Engl J Med 1991; 324 (24): 1716-25.Hardman J.G, Limbird L.E, Gilman A.G. Insel PA Analgesic-antipyretics and antiinflammatory agents and drug employed in the treatment of gout. In Goodman and Gilman's: The Pharmacological Basis for Therapeutics, 9th ed.; McGraw-Hill: New York, NY, USA, 1996; p. 617-57.McCormack K. Non-steroidal anti-inflammatory drugs and spinal nociceptive processing. Pain 1994; 59: 9-43.Melo-Carrillo A, Strassman A.M, Nir R et al. Stratton and Rami Burstein. Fremanezumab - A Humanized Monoclonal Anti-CGRP Antibody - Inhibits Thinly Myelinated (Ad) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci 2017; 37 (44): 10587-96.Ebersberger A, Averbeck B, Messlinger K, Reeh PW. Release of substance P, calcitonin gene-related peptide and prostaglandin E2 from rat dura mater encephali following electrical and chemical stimulation in vitro. Neurosci 1999; 89: 901-7.Zhang X.C, Kainz V, Jakubowski M et al. Localization of COX-1 and COX-2 in the intracranial dura mater of the rat. Neurosci Lett 2009; 452: 33-6.Ellrich, J, Schepelmann K, Pawlak M, Messlinger K. Acetylsalicylic acid inhibits meningeal nociception in rat. Pain 1999; 81: 7-14.Levy D, Zhang X.C, Jakubowski M, Burstein R. Sensitization of meningeal nociceptors: Inhibition by naproxen. Eur J Neurosci 2008; 27: 917-22.Buzzi M.G, Sakas D.E, Moskowitz M.A. Indomethacin and acetylsalicylic-acid block neurogenic plasma-protein extravasation in rat dura mater. Eur J Pharmacol 1989; 165: 251-8.Kaube H, Hoskin K.L, Goadsby P.J. Intravenous acetylsalicylic-acid inhibits central trigeminal neurons in the dorsal horn of the upper cervical spinal-cord in the cat. Headache 1993; 33: 541-4.Tassorelli C, Greco R, Armentero M.T et al. A role for brain cyclooxygenase-2 and prostaglandin-E2 in migraine: Effects of nitroglycerin. Int Rev Neurobiol 2007; 82: 373-82.Pardutz A, Szatmari E, Vecsei L, Schoenen J. Nitroglycerin-induced nNOS increase in rat trigeminal nucleus caudalis is inhibited by systemic administration of lysine acetylsalicylate but not of sumatriptan. Cephalalgia 2004; 24: 439-45.Varga H, Pardutz A, Vamos E et al. Cox-2 inhibitor attenuates NO-induced nNOS in rat caudal trigeminal nucleus. Headache 2007; 47: 1319-25.Yang G.Y, Lee M.K, Bae Y.C, Ahn D.K. Intracisternal administration of COX inhibitors attenuates mechanical allodynia following compression of the trigeminal ganglion in rats. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33: 589-95.Breder C.D, Smith W.L, Raz A et al. Distribution and characterization of cyclooxygenase immunoreactivity in the ovine brain. J Comp Neurol 1992; 322: 409-38.Breder C.D, Dewitt D, Kraig R.P. Characterization of inducible cyclooxygenase in rat brain. J Comp Neurol 1995; 355: 296-315.Shin M.C, Jang M.H, Chang H.K et al. Modulation of cyclooxygenase-2 on glycine- and glutamate-induced ion currents in rat periaqueductal gray neurons. Brain Res Bull 2003; 59: 251-6.Vaughan C.W. Enhancement of opioid inhibition of GABAergic synaptic transmission by cyclo-oxygenase inhibitors in rat periaqueductal grey neurones. Br J Pharmacol 1998; 123: 1479-81.Leith J.L, Wilson A.W, Donaldson L.F, Lumb B.M. Cyclooxygenase-1-derived prostaglandins in the periaqueductal gray differentially control C- vs. A-fiber-evoked spinal nociception. J Neurosci 2007; 27: 11296-305.Koistinaho J, Chan P.H. Spreading depression-induced cyclooxygenase-2 expression in the cortex. Neurochem Res 2000; 25: 645-51.Miettinen S, Fusco F.R, Yrjanheikki J et al. Spreading depression and focal brain ischemia induce cyclooxygenase-2 in cortical neurons through N-methyl-D-aspartic acid-receptors and phospholipase A2. Proc Natl Acad Sci USA 1997; 94: 6500-5.Yokota C, Inoue H, Kuge Y et al. Cyclooxygenase-2 expression associated with spreading depression in a primate model. J Cereb Blood Flow Metab 2003; 23: 395-8.Balfour J.A, Fitton A, Barradell L.B. Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions. Drugs 1996; 51: 639-57.Hillstrom C, Jakobsson J.G. Lornoxicam: pharmacology and usefulness to treat acute postoperative and musculoskeletal pain a narrative review. Expert Opin Pharmacother 2013; 14 (12): 1679-94.Ксефокам Рапид - официальная инструкция по применению. http: //grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=fa943cbf-5cd8-4e53-8923-2ef77ae5f4b4&t= /